|Day Low/High||2.98 / 3.08|
|52 Wk Low/High||2.96 / 9.02|
The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Deals, though, weren't the only mover of share prices.
Stock futures mostly lower Monday morning amid a slump in crude oil prices.
The Nasdaq-listed cancer drug developer is up 43% in premarket trading after promising shareholders special dividends worth more than its closing share price on Friday.
U.S. stock futures are mixed Monday, with futures for the Dow slightly lower; Britain's pound hit its lowest level against the U.S. dollar in more than two months.
Company to Sell ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Stocks hold slightly lower on Wednesday as the Dow Jones Industrial Average hovers around 40 points below its 20,000 milestone.
The Dow Jones Industrial Average holds agonizingly close to the 20,000 milestone on Wednesday morning after days of flirting with the level.
The drug was one of the most important in the company's pipeline, which is undergoing a strategic review.
Stock futures are mixed Wednesday, with the Dow Jones Industrial Average's 20,000 milestone still within reach.
Company now plans to provide results of ongoing strategic pipeline review in January
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the January 2017 expiration.
In trading on Thursday, shares of Merrimack Pharmaceuticals Inc. crossed above their 200 day moving average of $6.12, changing hands as high as $6.73 per share.
No matter who wins the election, Jim Cramer says, there are ways to make money.
Acceptance further validates Merrimack's leadership in development and manufacturing of complex liposomal formulations
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the June 2017 expiration.
Merrimack Pharmaceuticals' (MACK) stock rating was reduced to 'neutral' at JPMorgan earlier today.
The first day of trading in the fourth quarter was rough as stocks declined Monday.
U.S. stocks closed lower on Monday amid lower construction spending, mostly strong auto sales, and better-than-expected manufacturing data. Crude oil increased and utilities lagged.